Nonerosive Reflux Disease Treatment Market Information, Figures and Analytical Insights 2018 to 2026(Based on the drug type nonerosive reflux disease treatment market is segmented into following: Proton pump inhibitors H2 – blockers Antacids Prokinetics

Patients with classical symptoms of gastroesophageal reflux disease (GERD) with normal esophageal mucosa (i.e. without inflammation) are generally identified to have Nonerosive reflux disease (NERD). The patients with nonerosive reflux disease have no common symptoms. Nonerosive reflux disease patient are one who have normal esophagus during endoscopy but GERD like symptoms. 50 to 70% patients with GERD and more than 49% patients with heartburn tend to have nonerosive reflux disease. Proton pump inhibitors (PPI) are therapeutically most efficient drugs in nonerosive reflux disease treatment though complete symptom control is low. H2 – blockers have low success rate in nonerosive reflux treatment but are having high usage. Reduced success rate of proton pump inhibitors in patients with GERD and heartburn is attributed to co-existing nonerosive reflux disease. Success of antireflux surgery in nonerosive reflux disease treatment is low when compared to erosive reflux disease. Antacids, Proton pump inhibitors and H2 – blockers are used in nonerosive reflux disease treatment and in case of chronic cases antireflux surgery is done.

50 to 70% patients with GERD and 49% patients with heartburn tend to have nonerosive reflux disease, hence increasing prevalence of GERD and heartburn attributing to growth of nonerosive reflux disease treatment market. Development of GERD, Heartburn and nonerosive reflux disease is correlating to increasing prevalence of obesity and other dietary factors which are driving nonerosive reflux disease treatment market. Consequential impact on health related quality of life along with work related productivity is indicative of more chances to develop NERD which in term driving nonerosive reflux disease treatment market. Various studies have concluded that patients with nonerosive reflux disease have 20 to 30% less chances of getting relief from acid-blocking drugs hence making it difficult to treat nonerosive reflux disease with PPI. Non-availability of efficient treatment acting as a restraint in nonerosive reflux disease treatment market growth. Difficulty in diagnosis of nonerosive reflux disease further makes treatment difficult attributing to low nonerosive reflux disease market growth. Higher doses of proton pump inhibitor drugs are reported to develop adverse events further making nonerosive reflux disease treatment difficult. There is no treatment strategy established for nonerosive reflux disease treatment.

Request Free Sample Report@ https://www.factmr.com/connectus/sample?flag=S&rep_id=1098

The global nonerosive reflux disease treatment market is classified on the basis of product type, distribution channel and region

Based on the drug type nonerosive reflux disease treatment market is segmented into following:

Proton pump inhibitors
H2 – blockers
Antacids
Prokinetics
Based on the distribution channel nonerosive reflux disease treatment market is segmented into following:

Retail pharmacies
Hospital pharmacies
Online pharmacies
Various studies are going to develop strategy for treatment and diagnosis enhancing growth on nonerosive reflux disease market. Many studies are going on to distinguish nonerosive reflux disease patients from those with erosive esophagitis to make diagnosis and nonerosive reflux disease treatment efficient. Rising clinical studies in nonerosive reflux disease treatment are expected to drive market growth over forecast period. Advanced drug molecule development in proton pump inhibitor class is expected to improve PPI result in nonerosive reflux disease treatment. By drug type proton pump inhibitors segment is most preferred for nonerosive reflux disease treatment. By distribution channel retail pharmacies segment is expected to dominate due high preference. Increased studies to evaluate nonerosive reflux disease diagnosis and treatment is further attributed to drive nonerosive reflux disease treatment market.

Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1098

On the basis of geography, global nonerosive reflux disease treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Region wise North America is most lucrative market due increased prevalence of gastroesophageal reflux disease (GERD) and heartburn. Health related lifestyle correlating to obesity in North America is responsible for increasing nonerosive reflux disease treatment market and is only expected to grow. Nonerosive reflux disease is most common in patients with GERD and prevalence of gastroesophageal reflux disease (GERD) in North America (20%), Europe (9-17%) Asia Pacific (2-5%) once a week which is further responsible for nonerosive reflux disease treatment.

Key major players in the nonerosive reflux disease treatment market are: AstraZeneca plc, Eisai Co, GlaxoSmithKline PLC; Takeda Pharmaceutical Co., Ltd, Johnson & Johnson, Daewoong Pharmaceutical Co., Ltd.; Ironwood Pharmaceuticals, Inc.; SRS Pharmaceuticals Pvt. Ltd.; and SFJ Pharmaceuticals Group

The report covers exhaustive analysis on:

Nonerosive reflux disease treatment Market Segments
Nonerosive reflux disease treatment Market Dynamics
Historical Actual Market Size, 2013 - 2017
Nonerosive reflux disease treatment Market Size & Forecast 2018 to 2024
Nonerosive reflux disease treatment Agents Current Trends/Issues/Challenges
Competition & Companies involved
Nonerosive reflux disease treatment Market Drivers and Restraints
Regional analysis includes

North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size recent industry trends
Key Competition landscape
Strategies for key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Report Analysis@ https://www.factmr.com/report/1098/nonerosive-reflux-disease-treatment-market

About US
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Rohit Bhisey
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - http://theguardiantribune.com

This release was published on openPR.